Industry – Page 15 – Swanson Reed | Specialist R&D Tax Advisors

GTL Americas and Hyundai ENG America Partner for $3.5 Billion Green Fuel Project

ClearFlame Engine Technologies Receives Funding to test Clean Diesel-style Fuel

GTL Americas (GTLA) is set to embark on a groundbreaking $3.5 billion industrial project in Jefferson County, Arkansas. The company’s ambitious endeavor is to produce 1.7 million gallons of environmentally-friendly motor fuel daily, a significant milestone in the renewable energy sector. In this exciting venture, GTLA has joined forces with Hyundai ENG America, Inc. (Hyundai) for the construction of a colossal facility sprawled across an 1,800-acre site, located just 13 miles north of Pine Bluff.

The project, slated to commence within the next 18 months, is anticipated to unfold in four phases and could reach completion by 2029. It’s worth noting that this project holds the distinction of being the largest industrial initiative in the history of Arkansas and is set to employ approximately 225 workers, with the potential for further cost escalation as it progresses.

The GTLA project in Jefferson County represents a significant leap towards sustainability, as it will convert natural gas into 1.7 million gallons of ultra-clean transportation fuels daily. Additionally, it will generate 150 MW of carbon-free steam-generated electricity. Notably, the construction phase and commissioning period alone will create an estimated 2,500 jobs.

GTLA’s vision is to establish Arkansas as the nation’s premier producer of ultra-clean, high-grade diesel, naphtha, and even jet fuel. Hyundai and S&B Engineers and Constructors, Ltd. (S&B) are collaborating to deliver the Front-End Engineering Design (FEED) and Engineering, Procurement, Construction, and Commissioning (EPCC) phases of this historic industrial project.

Upon completion, this facility will be the only one of its kind in the United States, further cementing GTL Americas’ position as a pioneer in sustainable energy solutions. The project is backed by Energy Security Partners, Hanwha Petrochemicals from Korea, and the Arkansas Teachers Retirement Funds.

The distribution of these clean fuels will encompass various modes of transportation, including trucks, rails, and marine barges, with the added capability of connecting to product pipelines, supplying customers regionally and across the U.S. and international markets.

Arkansas was chosen as the ideal location for this facility due to its strategic advantages: it lies outside the hurricane zone, boasts excellent access to railroads, interstate highways, airports, and its central geographic location in the country.

GTL Americas, headquartered in Little Rock, Arkansas, is spearheading a remarkable gas-to-liquids (GTL) project with a daily capacity of 33,000 barrels. This cutting-edge plant will utilize the Fischer-Tropsch (FT) technology to transform pipeline natural gas into clean liquid transportation fuels and specialty chemicals. With a construction workforce of over 2,500 and around 250 permanent employees, this world-class project is poised to redefine the energy landscape in Arkansas and beyond.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Unlocking the Future of Healthcare: Gero’s Epigenetic Biomarker Discovery

Gero, a biotechnology startup, has recently announced a partnership with FOXO Technologies. FOXO is the creator of a saliva-based epigenetic technology while Gero is creating therapeutics against chronic diseases with a mission to slow down human aging itself.

Epigenetic biomarkers are a hot topic in the world of medical research, and Gero is harnessing their potential to transform healthcare. These biomarkers provide a window into the way genes are regulated and can offer crucial insights into various aspects of health, from disease risk to aging.

The companies have not yet signed a letter of intent, but “a deal will happen,” Gero CEO Peter Fedichev said. The scientific, technical, and financial details are still being worked out.

Gero’s partnership with FOXO Technologies could be a game-changer. FOXO proteins play a crucial role in regulating genes associated with longevity and age-related diseases. By leveraging FOXO technologies, Gero aims to uncover a treasure trove of epigenetic biomarkers that could reshape healthcare as we know it.

Aging is a complex process, and Gero’s efforts are dedicated to unraveling its mysteries. By understanding the epigenetic changes that occur as we age, Gero seeks to develop innovative therapies and interventions that promote healthy aging and extend our lifespan.

One of the most exciting aspects of Gero’s work is its potential for precision medicine. Epigenetic biomarkers can help tailor treatments to individual patients, ensuring they receive the right care at the right time. This personalized approach has the potential to revolutionize how we treat and prevent diseases.

As Gero advances its epigenetic biomarker discovery through FOXO Technologies, the possibilities for the future of healthcare are endless. Imagine a world where diseases are detected and treated before they even manifest symptoms, where aging is a graceful process, and where each individual’s health journey is unique.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Breaking New Ground: Biodel AG’s Series A Funding and Promising R&D

Biodel AG, a pioneering company in the field of biotechnology, is making waves with its recent Series A funding round. With an infusion of capital, the company is poised to take its cutting-edge research and development (R&D) efforts to the next level.

Securing Series A funding is a significant milestone for any startup, and Biodel AG is no exception. The company’s recent success in raising funds demonstrates the industry’s confidence in its vision and potential. This financial boost will enable Biodel AG to accelerate its R&D initiatives, bringing innovative solutions to the forefront of agriculture.

Biodel AG has long been dedicated to pushing the boundaries of nature to restore sustainability to our food supply. The company’s R&D efforts focus on developing biological products for crop and livestock production, based upon their proprietary microbial and amino acid ingredients. With these development efforts, they hope to develop the essential biological inputs and practices necessary to reverse the impact of climate change.

Biodel AG’s R&D efforts are summarized in three key areas:

Produce Nitrogen-Fixing, Photosynthetic Autotrophs
Produce Isoprenoid Amino Complex®
Manufacture Sequester® Soil Amendment & BioFertilizer Products

Biodel AG’s R&D endeavors have the potential to shape the future of healthcare by introducing innovative therapies, improving treatment outcomes, and enhancing patient experiences. With the Series A funding in place, the company is better equipped than ever to bring these transformative solutions to fruition.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Akkio Raises $15M in Series A Funding

Akkio, Inc., the Massachusetts-based trailblazer in AI technology, has secured a significant milestone with a $15 million series A funding round led by Bain Capital Ventures and Pandome, Inc. This infusion of capital, totaling $18 million for Akkio, is a resounding endorsement of their vision. The funds will serve to fast-track the commercialization of Akkio’s transformative AI platform, promising users an intuitive AI assistant to revolutionize data-driven decision-making.

The company’s standout proposition lies in its no-code platform, a game-changer for enterprises seeking to harness the power of AI. By simplifying AI development and deployment, Akkio empowers business analysts to swiftly integrate AI capabilities into their workflows, unlocking insights that drive growth. Tasks as diverse as fraud detection, sales funnel optimization, and churn reduction can now be empowered with AI’s predictive prowess, without the need for extensive coding expertise.

Akkio’s dedication to innovation is palpable through its AI-driven enhancements. Among these is the chat data prep feature, enabling seamless automation of data cleaning and preparation through natural language conversations. The Chat Explore capability further empowers data analysts by enabling interactions with data using GPT-4, fostering the identification of patterns and dynamic visualization creation. The Forecasting model is another jewel in Akkio’s crown, predicting inventory availability and sales performance based on real-time data analysis.

The company’s customer roster already boasts heavyweights like Ellipsis Marketing, AngioDynamics, and Standard Industries. These businesses, among hundreds of others, are leveraging Akkio’s AI-enabled solutions to augment internal processes and elevate decision-making efficiency.

Akkio’s ascent aligns with the growing trend of no-code AI development, a response to the surging demand for AI capabilities amid a dearth of data science talent. This arena has seen contenders like Google AutoML, Obviously AI, and Fritz AI emerge. According to Gartner, nearly two-thirds of app development is expected to transition to low-code/no-code solutions by 2024.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Torch.AI Ignites Innovation with All-Source Fusion Lab for AI Research

Torch.AI, renowned for pioneering Data Infrastructure AI, has unveiled its latest initiative: the Torch.AI All-Source Fusion Lab. Housed at the company’s Kansas City headquarters, this cutting-edge facility is set to drive AI innovation and research, revolutionizing how complex data is harnessed for real-time insights.

The lab serves as a collaborative hub, uniting data engineers, scientists, developers, and analysts to explore the potential of machine learning and AI technologies. By converting intricate data into actionable information, the lab aims to boost productivity and enhance decision-making processes.

Torch.AI’s focus extends beyond technology to address societal challenges. With initial emphasis on swiftly analyzing data from diverse sources, including publicly available information, the lab aims to contribute to crucial fields like countering human trafficking, ensuring school safety, and addressing political and national threats.

Brian Weaver, CEO of Torch.AI, sees the facility as a convergence point for regional and national experts, tackling intricate issues with collective intelligence. He envisions the lab as an open platform, inviting public participation in research sessions, thereby fostering a collaborative ecosystem in the Kansas City region.

Already bearing fruit, the lab has facilitated the development of groundbreaking patents and technologies, including the Generative Graph Auto-Oriented Transformer (GOAT™), an AI-driven data processing system. This underscores Torch.AI’s commitment to innovation and its application to real-world challenges.

Jason Eidam, Chief of Staff and Head of Strategy at Torch.AI, highlights the transformative role the lab plays. It serves as a space where clients and employees engage in experiential collaboration, fueling innovation across diverse sectors, from security and underwriting to anti-money laundering and fraud detection.

The Torch.AI All-Source Fusion Lab boasts state-of-the-art amenities, such as video-teleconferencing capabilities, designed to facilitate meaningful collaborations. As Torch.AI continues to grow, it envisions secure environments for classified work, ensuring the protection of sensitive information.

Torch.AI’s strides in AI research and development are underpinned by their commitment to harnessing technology for societal progress. With the All-Source Fusion Lab, Torch.AI is lighting the path for cutting-edge innovation, making a meaningful impact on both local and global scales.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Alpenglow Biosciences Awarded $1.6M Grant for AI-Enabled 3D Imaging

Alpenglow Biosciences, a visionary biotechnology company, has secured a remarkable $1.6 million grant to advance its pioneering work in artificial intelligence (AI)-enabled smart microscopy and 3D spatial biology. With a focus on enhancing cancer diagnostics, Alpenglow is set to revolutionize the field of pathology by harnessing the power of AI and 3D imaging.

Building on its patented multi-resolution 3Di platform for 3D spatial biology, Alpenglow Biosciences will collaborate with CorePlus, a leading pathology laboratory based in Puerto Rico. Together, they aim to propel pathology from 2D and qualitative analysis into the realm of 3D and quantitative precision.

Dr. Nicholas Reder, MD, MPH, and CEO of Alpenglow Biosciences, expressed enthusiasm about the company’s latest award, stating, “We are excited to continue to lead the field of 3D spatial biology and develop smart microscopy solutions to address cancer with this latest award.” The grant will enable the development of a smart microscopy platform, utilizing Alpenglow’s multi-resolution open-top light sheet microscope.

The key innovation lies in Alpenglow’s ability to process massive microscopy datasets at remarkable speed, using their proprietary AI. This advancement aims to swiftly identify regions of interest within large datasets, leading to higher-resolution imaging and more comprehensive quantitative analysis. The incorporation of NVIDIA Holoscan and NVIDIA IGX is expected to further elevate Alpenglow’s imaging technology, facilitating AI-powered edge computing on its 3Di platform.

Alpenglow’s vision extends beyond traditional pathology, tackling challenges in drug development and patient care. The company’s 3D spatial biology platform offers the potential to digitize entire tissue specimens non-destructively, leading to more accurate analysis and insights. By embracing AI and machine learning, Alpenglow seeks to quantify biomarkers and enhance diagnostic accuracy.

Partnering with CorePlus, Alpenglow aims to train AI models to recognize crucial tissue structures within 3D prostate biopsy images. This collaboration promises to elevate cancer diagnostics, improve precision, and facilitate the identification of areas that require further investigation.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Kriya Therapeutics’ $150M Boost to Series C Funding for Breakthrough Gene Therapies

Kriya Therapeutics, a biopharmaceutical company focused on gene therapy, has secured $150 million for its Series C funding round. This significant funding injection further propels the company’s mission to advance cutting-edge gene therapies and propel its drug development endeavors to new heights.

Having already secured a total of over $430 million in Series C funding, Kriya Therapeutics has now amassed an impressive $600 million since its inception in 2019. With a stronghold in California, the company has been consistently attracting substantial investments, with Patient Square Capital leading a $270 million Series C financing round in May 2022, following $80 million in Series A funding in May 2020 and $100 million in Series B.

Kriya Therapeutics has set its sights on groundbreaking advancements, planning to progress its undisclosed gene therapies into clinical trials. Alongside this, the company is dedicated to further enhancing its computational, engineering, and manufacturing platforms, ensuring that its therapies reach their full potential.

CEO Shankar Ramaswamy emphasized the company’s commitment to efficient gene therapy development, stating, “Our investments in world-class infrastructure and talent have supported our ability to move with unprecedented efficiency in the engineering and production of gene therapies.” With a passion for transformative healthcare, Kriya Therapeutics aims to provide better treatment options for patients battling metabolic, neurological, and ophthalmological conditions.

The company’s diverse pipeline encompasses therapies for metabolic disorders like diabetes and glycogen storage diseases, neurological diseases including epilepsy, and ophthalmological conditions like diabetic retinopathy. The acquisition of Redpin Therapeutics has further strengthened Kriya’s neurological gene therapy portfolio.

Though specifics about its treatments are yet to be revealed, Kriya Therapeutics made a splash at the 2023 American Society of Gene and Cell Therapy Annual Meeting. The company presented ten abstracts detailing its groundbreaking technology and manufacturing platforms, hinting at the transformative potential of its gene therapies.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

XCharge’s Texas Expansion: Igniting EV Charging Solutions with a Cutting-Edge Factory

The future of electric vehicles (EVs) is rapidly evolving, and the charging infrastructure is a make or break part of its growth. XCharge North America is taking a significant step towards shaping this future by establishing a production facility in the USA. Located in Kyle, Texas, this factory will pave the way for advanced DC fast charger manufacturing, contributing to the growth of EV adoption in the country.

Spanning an initial area of around 325 square meters, the new facility will expand to an impressive 1,858 square meters in the years to come. Situated in an industrial park, this facility will become a hub of innovation for the EV charging industry. This strategic location between Austin and San Antonio places it in a prime spot to cater to the EV charging needs of the region.

XCharge’s offerings include the powerful C6 DC charging station with up to 150 kW of power, as well as the Net Zero series. The Net Zero series, equipped with batteries from BYD for buffer storage, provides up to 210 kW of power for simultaneous charging of two electric vehicles. Moreover, this series features a Battery2Grid function, allowing surplus energy to be sold back to the grid during peak hours.

While the specific charging ports to be offered in the Texas-made charging posts are not disclosed in the announcement, XCharge NA’s focus is clear: to provide cost-efficient innovative EV solutions tailored to alleviate grid constraints and enhance EV accessibility. This dedication to innovative solutions that suit the local grid infrastructure sets XCharge in the rapidly evolving EV landscape.

Aatish Patel, President and Co-Founder of XCharge NA, emphasized the company’s commitment to partnership with the local community, including institutions like Texas State University. This collaborative approach aligns with XCharge NA’s vision of increasing job opportunities and driving economic growth through its operations.

By establishing this production facility in Texas, XCharge North America is not only contributing to the growth of EV charging infrastructure but also demonstrating the company’s dedication to enhancing EV accessibility, viability, and sustainability as a viable alternative transportation option. As EV adoption continues to rise, XCharge NA’s innovative solutions will play a pivotal role in shaping the future of transportation and energy.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Revolutionizing Carbon Capture: Compact Membrane Systems Secures $16.5 Million Series A Funding

Compact Membrane Systems (CMS), a groundbreaking player in the field of carbon capture, has recently announced the successful completion of an oversubscribed Series A funding round, securing an impressive $16.5 million. This funding not only highlights the confidence of investors but also marks a significant step forward in the fight against carbon emissions.

Headquartered in Newport, Compact Membrane Systems specializes in revolutionizing carbon capture technology. Their recent Series A funding round was led by Pangaea Ventures and featured the participation of notable investors such as GC Ventures, Solvay Ventures, Chevron Technology Ventures, and Technip Energies. This diverse group of investors underscores the broad spectrum of industries recognizing the importance of CMS’s carbon capture solutions.

CMS’s pioneering technology revolves around their advanced membrane systems. These innovative solutions have the potential to revolutionize industries that contribute to over 11% of global emissions, including sectors like steel, cement, and kiln-process operations. Unlike traditional carbon capture methods, which were expensive and energy-intensive, CMS’s modular and fully electrified solutions are designed to be contaminant-resistant, energy-efficient, and user-friendly. Remarkably, these solutions eliminate the need for regeneration, steam, or chemical solvents.

The implications of CMS’s breakthrough technology are far-reaching. By addressing emissions from industries responsible for a significant portion of global carbon output, the company is making a substantial contribution to a more sustainable future. What’s even more impressive is CMS’s ambitious timeline – aiming to deliver a low-cost, fully electrified carbon capture solution by 2026.

Erica Nemser, the CEO of Compact Membrane Systems, expressed her enthusiasm about these developments, stating, “This oversubscribed funding round catalyzes our ability to deliver large projects.” This funding will not only accelerate the company’s carbon capture solutions but also advance their work in olefins separation, enhancing production in chemical plants.

Beyond their groundbreaking technology, CMS is known for its distinctive work culture. Based in Wilmington, Delaware, the company offers a platform for personal growth, autonomy, and the opportunity to contribute to a cleaner future. With a collaborative work culture and a flat organizational structure, CMS fosters a spirit of learning and innovation.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Iontra: Pioneering the Future of Battery Charging Technology

In the realm of technological innovation, few advancements are as critical as those that power our devices. Iontra Inc, a trailblazing Colorado-based company, is reshaping the landscape of battery charging technology. In a recent milestone announcement, Iontra has secured an additional $29 million in funding, propelling its Series B fundraising total to an impressive $67 million and marking a total of $80 million raised to date. This injection of capital is set to accelerate the launch of their groundbreaking battery charger microcontroller (MCU), poised to transform the way we power our devices.

Iontra is on a mission to usher in a new era of battery charging technology, and their innovation promises to be a game-changer. The company is focusing its efforts on developing a low-cost and compact MCU designed to power battery-powered consumer products. These include a wide spectrum of devices we rely on daily, from smartphones to power tools and wearables.

By seamlessly integrating their MCU into these devices, Iontra is set to unlock the full potential of batteries while also driving down production costs. This innovation is poised to make a significant impact on the technology market, offering both superior battery performance and a reduced carbon footprint.

One of Iontra’s standout features is its focus on sustainability and efficiency. The company’s approach maximizes the use of critical battery minerals and materials, helping to pave the way for a more secure and sustainable energy future. Their technology extends the life of batteries, improves charging speed, and ensures a safer charging process – all without changing the design of battery cells or packs.

Iontra’s innovation extends beyond traditional battery charging methods. Their technology is predictive and responsive, actively safeguarding batteries during charging and discharging processes. This eradicates failure modes that have long plagued batteries, such as plating and dendrite formation, resulting in improved safety and performance.

Jeff Granato, the President and CEO of Iontra, envisions the transformative potential of their technology. “Fulfilling our mission to remove the greatest hurdles facing this global energy transition, we are on the path to make Iontra’s affordable charging solution available to the industry,” he states. With increasing support from both customers and investors, Iontra is poised to revolutionize the energy landscape.

In an era where the demand for battery minerals and materials is soaring due to electrification efforts, Iontra’s breakthrough technology couldn’t be timelier. As traditional charge management solutions fall short, Iontra’s innovative approach promises to bridge the gap, revolutionizing the way we power our devices while paving the way for a more sustainable energy future.

Iontra’s technology has undergone rigorous testing, accumulating approximately three million cycling hours across various battery types. The results have been validated by four independent research labs, showcasing the reliability and durability of their approach.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.